{"id":"W1980672928","doi":"10.1016/j.cllc.2012.01.003","title":"Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Erlotinib; Medicine; Oncology; Internal medicine; KRAS; Erlotinib Hydrochloride; Placebo; Lung cancer; Clinical endpoint; non-small cell lung cancer (NSCLC); Phases of clinical research; Epidermal growth factor receptor; Population; Clinical trial; Pharmacology; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03944556,0.006404862,0.007925593,0.001675125,0.003552297,0.003471133,0.003608681,0.005412313,0.01916523],"category_scores_gemma":[0.02506436,0.004806594,0.00454365,0.001288484,0.007591849,0.00275093,0.00150539,0.01044448,0.006506224],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002330464,"about_ca_system_score_gemma":0.009296964,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001043756,"about_ca_topic_score_gemma":0.002157957,"domain_scores_codex":[0.9808425,0.01191945,0.001204588,0.002733579,0.001897792,0.001402143],"domain_scores_gemma":[0.9927503,0.002192143,0.001231977,0.001037218,0.0009610926,0.001827277],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8837695,0.02145906,0.002680671,0.009233144,0.002370772,0.0004352716,0.0007210742,0.003324198,0.008942475,0.01295672,0.0111364,0.04297072],"study_design_scores_gemma":[0.8869413,0.06333611,0.002968064,0.00079285,0.001734586,0.0001841862,0.0001151534,0.002560861,0.001998622,0.005817479,0.03335338,0.0001974001],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.04382295,0.005889532,0.02046194,0.003460778,0.005118319,0.9113917,0.003918141,0.0005672946,0.005369391],"genre_scores_gemma":[0.07095821,0.001556455,0.02681508,0.00381281,0.001106683,0.8919031,0.0009389835,0.0000845348,0.002824105],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.03944556,"threshold_uncertainty_score":0.2086106,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06581369968642774,"score_gpt":0.4234511069001325,"score_spread":0.3576374072137048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}